Sparano J - Search Results

1

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Hurvitz SA, et al. Among authors: sparano j. Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23. Lancet Oncol. 2018. PMID: 29175149 Clinical Trial.

2

The potential role for biological therapy in the treatment of breast cancer.

Sparano JA, O'Boyle K. Sparano JA, et al. Semin Oncol. 1992 Jun;19(3):333-41. Semin Oncol. 1992. PMID: 1609298 Review. No abstract available.

3

Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer.

Sparano JA, Schwartz EL, Salva KM, Pizzillo MF, Wadler S, Wiernik PH. Sparano JA, et al. Am J Clin Oncol. 1990 Oct;13(5):374-8. doi: 10.1097/00000421-199010000-00002. Am J Clin Oncol. 1990. PMID: 2220657

4

Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer.

Wiernik PH, Sklarin NT, Dutcher JP, Sparano JA, Greenwald ES. Wiernik PH, et al. Among authors: sparano ja. Med Oncol. 1994;11(3-4):121-5. doi: 10.1007/BF02999859. Med Oncol. 1994. PMID: 7633831

5

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer.

Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH. Wadler S, et al. Among authors: sparano ja. Cancer Chemother Pharmacol. 1994;34(3):266-9. doi: 10.1007/BF00685088. Cancer Chemother Pharmacol. 1994. PMID: 8004762 Clinical Trial.

6

Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.

Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Sparano JA, et al. J Clin Oncol. 1993 Aug;11(8):1609-17. doi: 10.1200/JCO.1993.11.8.1609. J Clin Oncol. 1993. PMID: 8336197 Clinical Trial.

7

Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.

Sparano JA, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP. Sparano JA, et al. Cancer Res. 1993 Aug 1;53(15):3509-12. Cancer Res. 1993. PMID: 8339255 Clinical Trial.

8

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Sparano JA, et al. J Clin Oncol. 1993 Oct;11(10):1969-77. doi: 10.1200/JCO.1993.11.10.1969. J Clin Oncol. 1993. PMID: 8410122 Clinical Trial.

9

Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.

Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Sparano JA, et al. J Clin Oncol. 1993 Jun;11(6):1071-9. doi: 10.1200/JCO.1993.11.6.1071. J Clin Oncol. 1993. PMID: 8501493 Clinical Trial.

10

Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.

Sparano JA, Robert N, Silverman P, Lazarus H, Malik U, Venkatraj U, Sarta C. Sparano JA, et al. J Clin Oncol. 1996 Sep;14(9):2576-83. doi: 10.1200/JCO.1996.14.9.2576. J Clin Oncol. 1996. PMID: 8823338 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page